Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CD19 t-haNK- IV Administration
CD19 t-haNK- Administration · 2 trials · 2 indications
ORR in accordance with Lymphoma Response to Immunomodulatory Therapy Criteria(LYRIC). OS( Time from study treatment initiation to death)
| Arm | Type | Description |
|---|---|---|
| Open Label- Single Arm | OTHER | Open label: combination of Rituximab and investigational products |
| Name | Type | Description |
|---|---|---|
| CD19 t-haNK- IV Administration | BIOLOGICAL | CD19-Directed Therapies: CD19-targeted therapies, are biologic agents specifically designed to recognize and eliminate CD19-expressing B-cell malignancies. These therapies differ from traditional chemotherapy or small molecule inhibitors by leveraging the patient's immune system to achieve targeted cytotoxicity. Their mechanism of action involves direct binding to the CD19 antigen on malignant B cells, leading to immune-mediated cell death. |
| N-803 | DRUG | N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory T cells. N-803 SQ differs from other cytokine therapies due to its improved pharmacokinetic profile, enhanced in vivo activity, and reduced toxicity. |
| rituximab | DRUG | Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM. |
Inclusion Criteria: 1. Age ≥ 18 to ≤ 75 years old. 2. Able to understand and provide a signed informed consent that fulfils the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines. 3. Histologically or flow cytometry documented relapsed/refractory B-cell indol...
CD19 t-haNK is an investigational monoclonal antibody being studied for relapsed B-Cell Non-Hodgkin Lymphoma. It is in Phase 2 clinical development and has not been approved by the FDA. The drug is being evaluated in patients with relapsed or refractory disease.
CD19 t-haNK is being developed by ImmunityBio, Inc., which trades under the ticker IBRX. The company is conducting Phase 2 clinical trials to evaluate the drug in patients with relapsed B-Cell Non-Hodgkin Lymphoma.
CD19 t-haNK is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. Two Phase 2 trials are listed, one recruiting and one not yet recruiting, with a combined planned enrollment of 40 participants.
CD19 t-haNK is being studied in two Phase 2 trials. NCT07125872 is recruiting 20 participants in South Africa for relapsed B-Cell Non-Hodgkin Lymphoma. NCT07477366 is not yet recruiting 20 participants for a study combining CD19 t-haNK and NAI with rituximab in indolent Non-Hodgkin Lymphoma.
Yes, CD19 t-haNK is also known as CD19 t-haNK IV Administration. Both names refer to the same investigational drug being developed by ImmunityBio for the treatment of relapsed B-Cell Non-Hodgkin Lymphoma.